Article Text

PDF
P155 Safety of tiotropium respimat® add-on therapy in patients aged 6–17 years with symptomatic asthma

Abstract

C Vogelberg has participated in an advisory board for Boehringer Ingelheim;

SJ Szefler has received personal fees from Aerocrine, Boehringer-Ingelheim, Daiichi Sankyo, Genentech, GlaxoSmithKline, Merck, Novartis, and Roche, and research grants from GlaxoSmithKline;

E Hamelmann has received research grants and other fees from Boehringer Ingelheim and non-financial support from Boehringer Ingelheim;

A Boner has nothing to disclose;

P Moroni-Zentgraf is an employee of Boehringer Ingelheim;

M Engel is an employee of Boehringer Ingelheim;

G El Azzi is an employee of Boehringer Ingelheim;

H Finnigan is an employee of Boehringer Ingelheim;

M Vandewalker has received research grants and personal fees from Boehringer Ingelheim.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.